This observational study is for adults with oropharyngeal cancer (cancer of the middle part of the throat) who are having transoral robotic surgery (TORS). Researchers want to see if injecting EXPAREL® (Liposomal Bupivacaine), an FDA-approved pain medication, into the surgical area helps with pain and swallowing after surgery. They will compare patients who receive EXPAREL® to those who don't. The study will look at your pain control and swallowing ability (dysphagia) three months after surgery. You can join if you are 18 or older, having TORS, and can give consent. You cannot join if you are allergic to Bupivacaine or have a carnitine deficiency. The current status of this study is unclear.

Study design

This is an observational study involving 80 participants. It compares patients who receive Liposomal Bupivacaine to those who do not.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your pain control and swallowing will be measured for 3 months after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.